How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
30
CLLS Quote, Financials, Valuation and Earnings
Last price:
$3.48
Seasonality move
:
-16.28%
Day range:
$3.44 - $3.69
52-week range:
$1.10 - $5.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.35x
P/B ratio:
3.49x
Volume:
87.3K
Avg. volume:
53.1K
1-year change:
118.75%
Market cap:
$351.1M
Revenue:
$41.4M
EPS (TTM):
-$0.33
Analysts' Opinion
-
Consensus RatingCellectis SA has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.00, Cellectis SA has an estimated upside of 100% from its current price of $3.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $3.50.
Fair Value
-
According to the consensus of 4 analysts, Cellectis SA has 100% upside to fair value with a price target of $7.00 per share.
CLLS vs. S&P 500
-
Over the past 5 trading days, Cellectis SA has underperformed the S&P 500 by -10.47% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cellectis SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cellectis SA has grown year-over-year revenues for 7 quarters straight. In the most recent quarter Cellectis SA reported revenues of $35M.
Earnings Growth
-
Cellectis SA has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Cellectis SA reported earnings per share of $0.01.
Enterprise value:
278.1M
EV / Invested capital:
--
Price / LTM sales:
4.35x
EV / EBIT:
--
EV / Revenue:
3.70x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-8.01x
Price / Operating cash flow:
12.03x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$54.5M
Return On Assets:
-9.65%
Net Income Margin (TTM):
-47.45%
Return On Equity:
-31.08%
Return On Invested Capital:
-15.69%
Operating Margin:
16.76%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $16.5M | $29.1M | $75.2M | $16.2M | $35M | |
| Gross Profit | $2M | $9.7M | $54.5M | $11.5M | $30M | |
| Operating Income | -$85.9M | -$90.4M | -$34.7M | -$12.8M | $5.9M | |
| EBITDA | -$67.8M | -$71.2M | -$13.9M | -$8.1M | $10.9M | |
| Diluted EPS | -$11,692,898.63 | -$1.05 | -$0.33 | -$0.23 | $0.01 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $235.8M | $140.3M | $96.5M | $294.4M | $221.2M | |
| Total Assets | $412.9M | $279.6M | $209.7M | $395.9M | $343M | |
| Current Liabilities | $49.6M | $53M | $44M | $165.7M | $148.6M | |
| Total Liabilities | $150.7M | $134M | $133.6M | $266.5M | $242.6M | |
| Total Equity | $262.1M | $145.6M | $76.1M | $129.4M | $100.5M | |
| Total Debt | $104.6M | $86.3M | $95.3M | $106.8M | $101M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$66.1M | $62M | -$29.9M | -$6.1M | -$1.6M | |
| Cash From Investing | -$2M | -$99.8M | -$68.8M | $22.3M | -$3.3M | |
| Cash From Financing | $36.7M | $128.5M | -$9M | -$4M | -$4.1M | |
| Free Cash Flow | -$67.4M | $59.6M | -$34.7M | -$6.9M | -$4M | |
CLLS
Sector
Market Cap
$351.1M
$23.3M
Price % of 52-Week High
63.87%
48.38%
Dividend Yield
0%
0%
Shareholder Yield
-0.63%
-1.67%
1-Year Price Total Return
118.75%
-21.73%
Beta (5-Year)
2.833
0.502
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.81
200-day SMA
Buy
Level
$2.99
Bollinger Bands (100)
Sell
Level
3.4 - 4.64
Chaikin Money Flow
Sell
Level
-166.7K
20-day SMA
Sell
Level
$4.07
Relative Strength Index (RSI14)
Sell
Level
32.28
ADX Line
Sell
Level
31.19
Williams %R
Buy
Level
-93.8679
50-day SMA
Sell
Level
$4.46
MACD (12, 26)
Buy
Level
0.95
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Sell
Level
-133.6K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.8589)
Sell
CA Score
(Annual)
Level (-2.1974)
Sell
Beneish M-Score
(Annual)
Level (50.3205)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.19)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Stock Forecast FAQ
In the current month, CLLS has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CLLS average analyst price target in the past 3 months is $7.00.
-
Where Will Cellectis SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cellectis SA share price will rise to $7.00 per share over the next 12 months.
-
What Do Analysts Say About Cellectis SA?
Analysts are divided on their view about Cellectis SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cellectis SA is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Cellectis SA's Price Target?
The price target for Cellectis SA over the next 1-year time period is forecast to be $7.00 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CLLS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cellectis SA is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of CLLS?
You can purchase shares of Cellectis SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cellectis SA shares.
-
What Is The Cellectis SA Share Price Today?
Cellectis SA was last trading at $3.48 per share. This represents the most recent stock quote for Cellectis SA. Yesterday, Cellectis SA closed at $3.50 per share.
-
How To Buy Cellectis SA Stock Online?
In order to purchase Cellectis SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CLLS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CLLS
Sector
P/E ratio
--
23.47x
PEG ratio
--
-0.01x
P/B ratio
3.49x
1.75x
Price / LTM sales
4.35x
1.53x
Growth Metrics
CLLS
Sector
Revenue growth
116.15%
3.62%
Earnings growth
102.52%
9.09%
Revenue (5-year growth)
22.22%
6.22%
Earnings forecast
-$0.11
-$0.19
Profitability
CLLS
Sector
Profitability FY 2024
$21.6M
$2.6M
Return on invested capital
-15.69%
-33.62%
Return on assets
-9.65%
-29.68%
Return on equity
-31.08%
-38.98%
Earnings Date
Last Earnings Date
Nov
7
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
6
Balance Sheet
CLLS
Sector
Total cash
$192.2M
$25M
Short term investments
$117.1M
$23.9M
Total assets
$392.6M
$71.9M
Long term debt
$101M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
59
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
58
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
61
SLAB alert for Feb 5
Silicon Laboratories, Inc. [SLAB] is up 0.91% over the past day.
Buy
73
ENPH alert for Feb 6
Enphase Energy, Inc. [ENPH] is down 8.53% over the past day.
Sell
25
MRCY alert for Feb 5
Mercury Systems, Inc. [MRCY] is up 2.61% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
